LogicMark's Losses Widen Amidst Revenue Growth, OTC Transition

TL;DR

**LGMK is burning cash and got delisted, but a cash infusion offers a glimmer of hope for its struggling PERS business.**

AI Summary

LogicMark, Inc. reported a net loss of $4.2 million for the six months ended June 30, 2025, an increase from the $3.8 million net loss in the same period of 2024. Operating loss also widened to $4.5 million from $3.9 million year-over-year. Despite these losses, the company significantly improved its liquidity, with cash and cash equivalents rising to $5.0 million as of June 30, 2025, from $3.8 million at December 31, 2024. Additionally, LogicMark invested $8.0 million in government securities and increased its working capital to $12.6 million from $3.3 million. Revenue for the six months ended June 30, 2025, grew to $5.4 million, up from $4.9 million in the prior year, driven by product sales to the United States Veterans Health Administration (VHA) and other channels. However, total operating expenses increased to $8.1 million from $7.2 million, primarily due to higher general and administrative costs of $4.6 million and increased depreciation and amortization of $993,472. The company's common stock transitioned from Nasdaq Capital Market to OTC Markets Group Inc. on June 2, 2025.

Why It Matters

LogicMark's widening net loss and operating loss, despite revenue growth, signal ongoing profitability challenges for investors. The significant increase in cash and investments, alongside improved working capital, suggests a stronger balance sheet, potentially providing a buffer for continued operations and strategic initiatives. However, the delisting from Nasdaq to OTC Markets Group Inc. could impact investor confidence and stock liquidity, making it harder for existing shareholders to exit and for new investors to enter. The company's reliance on the VHA for a majority of its prepaid contracts highlights a concentration risk, while its focus on personal emergency response systems (PERS) and connected care platforms places it in a competitive and evolving healthcare technology market.

Risk Assessment

Risk Level: high — LogicMark reported a net loss of $4.2 million and an operating loss of $4.5 million for the six months ended June 30, 2025, indicating continued unprofitability. The company's common stock was delisted from the Nasdaq Capital Market on June 2, 2025, and now trades on the OTC Markets Group Inc., which typically implies lower liquidity and increased risk for investors.

Analyst Insight

Investors should exercise extreme caution and consider the high risk associated with LGMK. While the company has improved its cash position to $5.0 million and invested $8.0 million in government securities, its persistent operating losses and recent delisting from Nasdaq are significant red flags. Monitor future filings for sustained profitability and a clear path to positive cash flow before considering any investment.

Financial Highlights

debt To Equity

0.12

revenue

$5.4M

operating Margin

-83.3%

total Assets

$23.5M

total Debt

$2.2M

net Income

$(4.2M)

eps

$(0.02)

gross Margin

N/A

cash Position

$5.0M

revenue Growth

+10.2%

Revenue Breakdown

Key Numbers

• $5.4M — Revenues (Increased from $4.9M for the six months ended June 30, 2024)
• $(4.2M) — Net Loss (Widened from $(3.8M) for the six months ended June 30, 2024)
• $(4.5M) — Operating Loss (Increased from $(3.9M) for the six months ended June 30, 2024)
• $5.0M — Cash and Cash Equivalents (Increased from $3.8M at December 31, 2024)
• $8.0M — Investments (New investment in government securities as of June 30, 2025)
• $12.6M — Working Capital (Significantly increased from $3.3M at December 31, 2024)
• 576,305,099 — Common Shares Outstanding (As of August 13, 2025, a substantial increase from 2,397,794 at December 31, 2024)
• $(0.02) — Net Loss Per Share (Diluted) (For the six months ended June 30, 2025, compared to $(45.30) in 2024 due to increased share count)

Key Players & Entities

• LogicMark, Inc. (company) — registrant
• Nasdaq Capital Market (regulator) — former stock exchange
• OTC Markets Group Inc. (regulator) — current stock exchange
• United States Veterans Health Administration (company) — major customer for product sales
• $4.2 million (dollar_amount) — net loss for six months ended June 30, 2025
• $4.5 million (dollar_amount) — operating loss for six months ended June 30, 2025
• $5.0 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $8.0 million (dollar_amount) — investments in government securities as of June 30, 2025
• $12.6 million (dollar_amount) — working capital as of June 30, 2025
• $5.4 million (dollar_amount) — revenues for six months ended June 30, 2025

FAQ

Risk Factors

• Widening Net and Operating Losses [high — financial]: The company reported a net loss of $4.2 million for the six months ended June 30, 2025, an increase from $3.8 million in the same period of 2024. The operating loss also widened to $4.5 million from $3.9 million year-over-year, indicating deteriorating profitability.
• Increased Operating Expenses [medium — financial]: Total operating expenses rose to $8.1 million from $7.2 million, primarily due to a significant increase in general and administrative costs to $4.6 million and higher depreciation and amortization of $993,472. This surge in expenses outpaced revenue growth.
• Stock Delisting from Nasdaq [medium — market]: LogicMark's common stock transitioned from the Nasdaq Capital Market to OTC Markets Group Inc. on June 2, 2025. This move typically signifies a lower market capitalization and can reduce liquidity and investor interest.
• Substantial Increase in Common Shares Outstanding [high — financial]: The number of common shares outstanding surged to 576,305,099 as of August 13, 2025, from 2,397,794 at December 31, 2024. This massive dilution significantly impacts earnings per share and shareholder value.
• Series C Redeemable Preferred Stock [low — regulatory]: The company has Series C Redeemable Preferred Stock with an aggregate liquidation preference of $2,000,000. While not a direct debt, the redemption features could pose a future financial obligation or impact equity.

Industry Context

LogicMark operates in the medical device and health technology sector, which is characterized by innovation, regulatory oversight (FDA), and competition from both established players and startups. The increasing demand for remote patient monitoring and telehealth solutions presents growth opportunities, but also requires significant R&D investment and market penetration strategies.

Regulatory Implications

As a medical device company, LogicMark is subject to stringent regulations from bodies like the FDA. Compliance with quality standards, manufacturing practices, and product approvals is critical. Any failure to comply can lead to product recalls, fines, and reputational damage, impacting sales and market access.

What Investors Should Do

1. Monitor expense control measures.
2. Evaluate the impact of stock dilution.
3. Assess the sustainability of liquidity improvements.
4. Track VHA contract performance.

Key Dates

• 2025-06-02: Stock Transition to OTC Markets — Indicates a downgrade in exchange listing, potentially impacting liquidity and investor perception.
• 2025-06-30: End of Second Quarter — Reporting period for the 10-Q, showing increased losses but improved liquidity.
• 2025-08-13: Common Shares Outstanding Date — Reflects a massive increase in share count, leading to significant dilution.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company has historically incurred more expenses than revenues, standing at $(113,408,294) as of June 30, 2025.)

Series C Redeemable Preferred Stock

A class of preferred stock that the issuer has the option or obligation to redeem (buy back) from shareholders under certain conditions. (Represents a potential future cash outflow or obligation for the company, with a liquidation preference of $2,000,000.)

Goodwill

An intangible asset that arises when one company acquires another for a price greater than the fair market value of its net assets. (Represents a significant portion of the company's assets ($3,143,662), suggesting past acquisitions.)

Right-of-use assets

Assets recognized under lease accounting standards, representing the right to use an underlying asset for the lease term. (Increased significantly to $348,843, indicating new or expanded leasing arrangements.)

Additional paid-in capital

The amount of money a company receives from selling stock above its par value. (Shows substantial capital raised through equity issuance, totaling $132,427,757.)

Year-Over-Year Comparison

For the six months ended June 30, 2025, LogicMark reported a 10.2% increase in revenue to $5.4 million, up from $4.9 million in the prior year. However, this revenue growth was overshadowed by a widening net loss of $4.2 million compared to $3.8 million and an increased operating loss of $4.5 million versus $3.9 million. While liquidity improved with cash rising to $5.0 million and significant investment in securities, operating expenses also climbed, driven by higher G&A costs, indicating pressure on margins.

Key Financial Figures

• $0.0001 — ,099 shares of common stock, par value $0.0001 per share, of the registrant issued and

Filing Documents

• ea0249423-10q_logic.htm (10-Q) — 682KB
• ea024942301ex31-1_logic.htm (EX-31.1) — 10KB
• ea024942301ex31-2_logic.htm (EX-31.2) — 10KB
• ea024942301ex32-1_logic.htm (EX-32.1) — 4KB
• ea024942301ex32-2_logic.htm (EX-32.2) — 4KB
• image_001.jpg (GRAPHIC) — 8KB
• 0001213900-25-075467.txt ( ) — 4697KB
• lgmk-20250630.xsd (EX-101.SCH) — 48KB
• lgmk-20250630_cal.xml (EX-101.CAL) — 39KB
• lgmk-20250630_def.xml (EX-101.DEF) — 220KB
• lgmk-20250630_lab.xml (EX-101.LAB) — 467KB
• lgmk-20250630_pre.xml (EX-101.PRE) — 237KB
• ea0249423-10q_logic_htm.xml (XML) — 432KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26 Part II. OTHER INFORMATION 27 Item 1.

Legal Proceedings

Legal Proceedings 27 Item 1A.

Risk Factors

Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27 Item 3. Defaults upon Senior Securities 27 Item 4. Mine Safety Disclosures 27 Item 5. Other Information 27 Item 6. Exhibits 28

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Financial Statements (Unaudited)

Item 1. Condensed Financial Statements (Unaudited) LogicMark, Inc. CONDENSED BALANCE SHEETS (Unaudited) June 30, December 31, 2025 2024 Assets Current Assets Cash and cash equivalents $ 5,013,959 $ 3,806,915 Investments 7,965,965 - Accounts receivable, net 148,968 4,355 Inventory 790,183 1,048,963 Prepaid expenses and other current assets 573,864 476,672 Total Current Assets 14,492,939 5,336,905 Property and equipment, net 60,761 112,605 Right-of-use assets, net 348,843 48,641 Product development costs, net of amortization of $ 614,581 and $ 397,340 , respectively 1,180,787 1,384,172 Software development costs, net of amortization of $ 765,757 and $ 428,803 , respectively 2,429,594 2,019,090 Goodwill 3,143,662 3,143,662 Other intangible assets, net of amortization of $ 6,809,203 and $ 6,428,305 , respectively 1,795,364 2,176,262 Total Assets $ 23,451,950 $ 14,221,337 Liabilities, Series C Redeemable Preferred Stock and Stockholders' Equity Current Liabilities Accounts payable $ 619,565 $ 750,336 Accrued expenses 902,736 1,053,301 Deferred revenue 400,026 225,195 Total Current Liabilities 1,922,327 2,028,832 Other long-term liabilities 326,228 - Total Liabilities 2,248,555 2,028,832 Commitments and Contingencies (Note 9) Series C Redeemable Preferred Stock Series C redeemable preferred stock, par value $ 0.0001 per share: 2,000 shares designated; 1 share issued and outstanding as of June 30, 2025 and December 31, 2024, respectively, aggregate liquidation preference of $ 2,000,000 as of June 30, 2025 and December 31, 2024, respectively 1,807,300 1,807,300 Stockholders' Equity Preferred stock, par value $ 0.0001 per share: 80,000,000 shares authorized Series F preferred stock, par value $ 0.0001 per share: 1,333,333 shares designated; 106,333 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively, aggregate liquidation preference of

View Full Filing

View this 10-Q filing on SEC EDGAR